Manjit Rahelu, the chief business officer of Arecor Therapeutics PLC (AIM:AREC), elaborates on the company's latest milestone. This development involves a groundbreaking collaboration aimed at reformulating a blockbuster oncology drug into a more efficient, ready-to-use liquid form. The advancement signifies a notable shift from the drug's previous, more complex powdered form, promising to enhance the ease of use and reduce preparation time significantly. Rahelu sheds light on the collaborative efforts, the technical aspects of this reformulation, and its implications for patient care, while also discussing Arecor's strategic direction and the impact of this achievement on the company's profile in the pharmaceutical industry.
Thomas Warner (TW): Could you share with us what you can about this morning's announcement from Arecor Therapeutics?
Manjit Rahelu (MR): We've announced an exciting collaboration based on a product we've developed in-house. It's a reformulation of a blockbuster oncology drug, now in a ready-to-use liquid format. This partnership, with a global medical products company, combines our in-house development capabilities with our partner's global R&D, manufacturing, and regulatory expertise. Our goal is to make this drug more efficient and convenient for patients and healthcare providers.
TW: What are the benefits of reformulating this oncology drug for patients?
MR: The current form of this drug is a complex, time-consuming, and potentially error-prone powder. By converting it into a ready-to-use liquid, we streamline the preparation process. This not only brings efficiencies to healthcare providers but also significantly reduces the waiting time for patients, enhancing the overall healthcare delivery experience.
TW: Could you elaborate on the technical aspects of this reformulation?
MR: Absolutely. The current blockbuster drug is in powder form, which is difficult to reconstitute. Our reformulation brings it into a liquid state, ready to be diluted to the required strength for each patient. This simplification of the process is a significant step forward in oncology treatment delivery.
TW: This announcement seems a bit different from Arecor's usual focus on diabetes. Can you comment on that?
MR: You're right, Thomas. While we are known for our work in diabetes, this project uses the same underlying technology. We selected this oncology drug as part of our in-house program because we saw its potential and how our technology could enhance it. This approach allows us to develop and add value to the product internally, maintaining more control and value.
TW: What are the broader benefits for Arecor in signing a deal like this?
MR: Partnering with a globally recognized company in this field is a key aspect of this deal. They bring immense expertise in development, regulatory affairs, manufacturing, and marketing. This partnership is a testament to our ability to attract top-tier partners and demonstrates our capacity to select the right candidates and develop value-driving collaborations.
TW: Finally, Manjit, since your appointment in April 2023, what unique contributions do you see Arecor bringing to these large commercial partnerships?
MR: Since joining Arecor, I've seen firsthand the depth of experience and expertise within our team. Our Arestat platform, coupled with our team's know-how, allows us to tackle challenging projects like transforming a powder into a stable, room-temperature liquid. It's this ability to enhance already great drugs that makes Arecor a valuable partner in the pharmaceutical industry.
TW: Thank you, Manjit, for these fascinating insights into Arecor Therapeutics' latest developments. We look forward to seeing the impact of this innovation on patient care in oncology.